PPARGC1A and Insulin resistance: In db/db mice, Liang et al. [46] found that EA treatment (five times per week for eight weeks) contracted the increase of fasting blood glucose, food intake, and body mass and maintained insulin levels via stimulation of skeletal muscle Sirtuin 1 (SIRT1)/peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α), suggesting the role of EA in improving insulin resistance.